Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life and gastrointestinal symptoms after conversion to Myfortic in maintenance renal transplant recipients on tacrolimus
2004-000782-35Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mycophenolate sodium (2 arms), sponsored by Novartis. Primary endpoints: Quality of life and Gastrointestinal symptoms. Started Nov 2005; status: completed.
02
Drugs
mycophenolate sodium
Beyond the preview
Go deeper on 2004-000782-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000782-35.